KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Prepaid Assets (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Prepaid Assets for 18 consecutive years, with $306.1 million as the latest value for Q1 2026.

  • For Q1 2026, Prepaid Assets rose 37.52% year-over-year to $306.1 million; the TTM value through Mar 2026 reached $306.1 million, up 37.52%, while the annual FY2025 figure was $237.1 million, 8.79% up from the prior year.
  • Prepaid Assets hit $306.1 million in Q1 2026 for Ionis Pharmaceuticals, up from $237.1 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $306.1 million in Q1 2026 and bottomed at $142.8 million in Q2 2022.
  • Average Prepaid Assets over 5 years is $196.2 million, with a median of $184.2 million recorded in 2024.
  • Year-over-year, Prepaid Assets increased 1.72% in 2024 and then soared 37.52% in 2026.
  • Ionis Pharmaceuticals' Prepaid Assets stood at $168.3 million in 2022, then increased by 22.1% to $205.4 million in 2023, then grew by 6.09% to $217.9 million in 2024, then increased by 8.79% to $237.1 million in 2025, then grew by 29.1% to $306.1 million in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $306.1 million, $237.1 million, and $243.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.